Targeting RTK Signaling Pathways in Cancer

Area of Science:

• Molecular Biology
• Oncology
• Cell Signaling

Background:

• The RAS/MAP kinase (MAPK) and RAS/PI3K/AKT pathways regulate fundamental cellular processes like proliferation, differentiation, and survival.
• Receptor Tyrosine Kinases (RTKs) initiate these signaling cascades upon ligand binding.
• Aberrant activation of these pathways in cancer promotes uncontrolled proliferation, survival, and metastasis.

Purpose of the Study:

• To review common mutations within the RAS/MAPK and RAS/PI3K/AKT signaling pathways in various cancers.
• To elucidate the resulting pathogenesis and molecular mechanisms driving cancer progression.
• To provide an overview of current and emerging therapeutic strategies targeting these mutated pathways.

Main Methods:

• Literature review of peer-reviewed articles and clinical trial data.
• Analysis of mutation frequencies and their correlation with cancer types.
• Synthesis of information on targeted therapies and their efficacy.

Main Results:

• Mutations in RTKs, Ras, B-Raf, PI3K, and AKT are frequently observed in diverse cancers.
• These mutations lead to constitutive pathway activation, fueling malignancy.
• Various targeted therapies, including small molecule inhibitors, are being developed and utilized.

Conclusions:

• Targeting the RAS/MAPK and RAS/PI3K/AKT pathways is a critical strategy in cancer therapy.
• Understanding specific mutations is key to selecting effective personalized treatments.
• Continued research is needed to overcome resistance mechanisms and improve therapeutic outcomes.